NuVasive Inc.

Nuvasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The company's principal product offering includes a minimally disruptive surgical platform, Maximum Access Surgery. The platform includes the company's proprietary software-driven nerve detection and avoidance systems, and Intraoperative Monitoring services and support; MaXcess, an integrated split-blade retractor system; and implants and biologics. The company's spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable surgeon access to the spine to perform restorative and fusion procedures.
  • TickerNUVA
  • ISINUS6707041058
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States

An increasingly favourable environment allows NUVASIVE to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of NUVASIVE (US), a company active in the Medical Equipment industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date December 22, 2020, the closing price was USD 52.28 and its expected value was estimated at USD 48.10.

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or 'the company') is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic p...

MarketLine Department

Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report

Summary Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Integra LifeSciences Holdings Corporation (Integra or 'the company') is a provider of medical technology solution. The company offers regenerative technologies, surgical solutions, and orthopedics and tissue technologies. Its products find application in burn and ti...

Nuvasive Inc: 1 director bought

A director at Nuvasive Inc bought 2,000 shares at 48.230USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Consumer Cyclical names continue to develop positively. (ex. APTV, WGO, CROX, NKE, SKX, MAT, RRGB, BKE, MIK, SIG, and DKS) • A few names in Consumer Staples are developing positively. (ex. INGR, MKC, and K) • A few names in the Materials Sector are developing positively (ex. CMP, and CMC)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Nuvasive Inc: 1 director bought

A director at Nuvasive Inc bought 2,000 shares at 48.230USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or 'the company') is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic p...

MarketLine Department

Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report

Summary Integra LifeSciences Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Integra LifeSciences Holdings Corporation (Integra or 'the company') is a provider of medical technology solution. The company offers regenerative technologies, surgical solutions, and orthopedics and tissue technologies. Its products find application in burn and ti...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

MarketLine Department

Zimmer Biomet Holdings Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Zimmer Biomet Holdings Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Zimmer Biomet Holdings Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its compet...

An increasingly favourable environment allows NUVASIVE to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of NUVASIVE (US), a company active in the Medical Equipment industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date December 22, 2020, the closing price was USD 52.28 and its expected value was estimated at USD 48.10.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch